{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T11:55:49Z","timestamp":1768564549374,"version":"3.49.0"},"reference-count":47,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013870","name":"Epilepsiatutkimuss\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013870","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008376","name":"Helsingin ja Uudenmaan Sairaanhoitopiiri","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008376","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007639","name":"Maire Taposen S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007639","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Epilepsia Open"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>Several antiseizure medications (ASMs) can be considered as first\u2010line treatment for glioma\u2010associated epilepsy (GAE). We aimed to find out, if there are subgroups of glioma patients which may benefit from different first\u2010line ASMs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>All diffuse glioma (grade 2\u20134) patients, who were in contact with Helsinki University Hospital Neurology or Oncology Departments during 2013\u20132015, were recognized from medical records. Follow\u2010up data was retrospectively collected of all GAE patients living in Helsinki for 5\u2009years from diagnosis of glioma, or until death.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 121 patients with GAE fulfilling inclusion criteria were identified. Forty\u2010nine (40.5%) had grade 2 glioma, 18 (14.9%) had grade 3 glioma, and 54 (44.6%) had grade 4 glioma. The most common first ASM was oxcarbazepine (39.2%), followed by levetiracetam (22.5%), carbamazepine (19.3%), phenytoin (10.8%) and valproic acid (8.3%). The first ASM was retained in use in 70 (57.9%) patients until the end of follow\u2010up. Among patients with low\u2010grade glioma, oxcarbazepine was favored, whereas grade 4 glioma patients more often received levetiracetam as first ASM. At the end of follow\u2010up, the retention rate of levetiracetam as first ASM was higher than retention rate of other ASMs in grade 4 glioma patients (<jats:italic>p<\/jats:italic> 0.002). Patients who initiated valproic acid as first ASM underwent more ASM changes than patients who initiated other first\u2010line ASM (<jats:italic>p<\/jats:italic> 0.005).<\/jats:p><\/jats:sec><jats:sec><jats:title>Significance<\/jats:title><jats:p>Levetiracetam seems to be a favorable first\u2010line treatment for GAE, especially for patients with grade 4 glioma. For grade 2\u20133 glioma patients, oxcarbazepine may be a reasonable option.<\/jats:p><\/jats:sec><jats:sec><jats:title>Plain Language Summary<\/jats:title><jats:p>Grade 2\u20134 gliomas are central nervous system tumors originating from glial cells, and epilepsy is common in glioma patients. We found that levetiracetam was favored as first antiseizure medication for patients with malignant, grade 4, glioma. For patients with slower\u2010growing tumors, grade 2\u20133 gliomas, oxcarbazepine may be a reasonable choice for first antiseizure medication. The findings highlight the need for individual assessment in the use of antiseizure medications in glioma patients.<\/jats:p><\/jats:sec>","DOI":"10.1002\/epi4.70007","type":"journal-article","created":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T05:39:37Z","timestamp":1746077977000},"page":"705-716","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Antiseizure medication choice in diffuse glioma: A single\u2010center population\u2010based experience"],"prefix":"10.1002","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6606-6251","authenticated-orcid":false,"given":"Leena","family":"Ollila","sequence":"first","affiliation":[{"name":"Department of Neurology, Epilepsia Helsinki, Member of ERN EpiCare, Neurocenter Helsinki University Hospital and University of Helsinki  Helsinki Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reina","family":"Roivainen","sequence":"additional","affiliation":[{"name":"Department of Neurology, Epilepsia Helsinki, Member of ERN EpiCare, Neurocenter Helsinki University Hospital and University of Helsinki  Helsinki Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,4,30]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474\u20104422(07)70103\u20105"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebr.2023.100586"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.10712"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ncl.2015.11.002"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp\u20102014\u2010308136"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.3171\/JNS\/2008\/108\/2\/0227"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/not109"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nov032"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdg502"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noad154"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474\u20104422(11)70047\u20103"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.3880"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10072\u2010019\u201004025\u20109"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.11.003"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2362"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/nop\/npab030"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.12074"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.16880"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noab152"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/nop\/npab059"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/not057"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11060\u2010016\u20102054\u20108"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29439"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.6563"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.17464"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11060\u2010017\u20102628\u20100"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2008.09.009"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebcr.2018.09.003"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11060\u2010017\u20102473\u20101"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1186\/1756\u20109966\u201028\u201060"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.17508"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.13670"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1528\u20101157.2001.04501.x"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11060\u2010018\u201003007\u20109"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2017.08.039"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365\u20102125.2005.02529.x"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.2174\/157488408785747656"},{"key":"e_1_2_12_39_1","doi-asserted-by":"publisher","DOI":"10.1053\/seiz.2000.0391"},{"key":"e_1_2_12_40_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.21.11.904.34513"},{"key":"e_1_2_12_41_1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/not170"},{"key":"e_1_2_12_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2019.04.019"},{"key":"e_1_2_12_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2014.05.031"},{"key":"e_1_2_12_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(21)00247\u20106"},{"key":"e_1_2_12_45_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp\u20102011\u2010300376"},{"key":"e_1_2_12_46_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12883\u2010016\u20100663\u20107"},{"issue":"4","key":"e_1_2_12_47_1","first-page":"489","article-title":"Levetiracetam: a review of its use in epilepsy","volume":"71","author":"Lyseng\u2010Williamson KA","year":"2011","journal-title":"Drugs"},{"key":"e_1_2_12_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2024.109919"}],"container-title":["Epilepsia Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/epi4.70007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T09:08:03Z","timestamp":1749805683000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/epi4.70007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,30]]},"references-count":47,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1002\/epi4.70007"],"URL":"https:\/\/doi.org\/10.1002\/epi4.70007","archive":["Portico"],"relation":{},"ISSN":["2470-9239","2470-9239"],"issn-type":[{"value":"2470-9239","type":"print"},{"value":"2470-9239","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,30]]},"assertion":[{"value":"2024-09-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}